Altogether, these findings suggest that MDA-7/IL-24-engineered T cells exhibit superior anticancer activity by offsetting multiple immune limiting factors in the tumor microenvironment and targeting cancer cells beyond an antigen-specific fashion [11]. The gene discussed is IL24; the disease is cancer.